法国局部晚期或转移性尿路上皮癌的流行病学、资源利用及治疗模式
Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in France.
作者信息
Joly Florence, Culine Stephane, Roupret Morgan, Tricotel Aurore, Casarotto Emilie, Brice Sandrine, Minacori Rafael, Vuillet Marthe, Thomas Marie-Catherine, Leyland Kirsten, Upadhyay Anil, Munro Vicki, Strunz-McKendry Torsten
机构信息
INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, Caen, France.
Clinical Research Department, Centre François Baclesse, Caen, France.
出版信息
Future Oncol. 2025 Mar;21(6):665-679. doi: 10.1080/14796694.2025.2459058. Epub 2025 Feb 20.
AIM
Describe real-world epidemiology, treatment patterns, health care resource utilization, and costs of locally advanced or metastatic urothelial carcinoma (la/mUC) in France.
PATIENTS & METHODS: Retrospective study including all adults with la/mUC diagnosis during January 2017 to December 2020 in the PMSI database.
RESULTS
Annual prevalence and incidence ranged from 36.4 to 38.9 and 16.4 to 18.5 cases per 100,000 people, respectively. Of the 25,314 patients with incident la/mUC, 37.6% did not receive first-line systemic treatment. Of the 14,656 patients who started first-line systemic treatment, 66.6%, 22.5%, and 10.9% received 1, 2, and 3 lines of therapy, respectively. Annual per-patient costs in second-/third-line setting ranged from €8803 to €16,012.
CONCLUSION
The substantial disease burden of la/mUC in France highlights the unmet need for new therapies.
目的
描述法国局部晚期或转移性尿路上皮癌（la/mUC）的真实世界流行病学、治疗模式、医疗资源利用情况及成本。
患者与方法
回顾性研究，纳入2017年1月至2020年12月期间在PMSI数据库中诊断为la/mUC的所有成年患者。
结果
年患病率和发病率分别为每10万人36.4至38.9例和16.4至18.5例。在25314例初发la/mUC患者中，37.6%未接受一线全身治疗。在14656例开始一线全身治疗的患者中，分别有66.6%、22.5%和10.9%接受了1、2和3线治疗。二线/三线治疗中每位患者的年度成本为8803欧元至16012欧元。
结论
法国la/mUC的巨大疾病负担凸显了对新疗法的未满足需求。
Zotero 插件